Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

PHASE3CompletedINTERVENTIONAL
Enrollment

1,236

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

February 17, 2020

Study Completion Date

April 16, 2020

Conditions
Acne Vulgaris
Interventions
DRUG

GDC 268 Lotion

GDC 268 is a topical lotion

DRUG

Clindamycin Phosphate Lotion 1%

Clindamycin Phosphate Lotion is an FDA-approved drug product

DRUG

GDC Vehicle Lotion

GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs

Trial Locations (34)

19103

Site 34, Philadelphia

27262

Site 06, High Point

27612

Site 32, Raleigh

29621

Site 08, Anderson

30263

Site 10, Newnan

32720

Site 45, DeLand

33014

Site 35, Miami Lakes

33145

Site 38, Miami

33162

Site 37, North Miami Beach

33180

Site 44, Aventura

33406

Site 01, West Palm Beach

33511

Site 36, Brandon

33609

Site 42, Tampa

33709

Site 26, St. Petersburg

33770

Site 41, Largo

37130

Site 03, Murfreesboro

37215

Site 04, Nashville

37421

Site 29, Chattanooga

43016

Site 19, Dublin

46168

Site 02, Plainfield

48346

Site 28, Clarkston

55432

Site 24, Fridley

60008

Site 05, Rolling Meadows

66215

Site 27, Overland Park

68134

Site 49, Omaha

72758

Site 22, Rogers

72916

Site 07, Fort Smith

77479

Site 43, Sugar Land

83704

Site 09, Boise

91324

Site 33, Northridge

92103

Site 30, San Diego

92708

Site 25, Fountain Valley

97030

Site 17, Gresham

02886

Site 20, Warwick

All Listed Sponsors
lead

Balmoral Medical company

INDUSTRY

NCT03717506 - Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris | Biotech Hunter | Biotech Hunter